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INTRODUCTION
The known differences in the proportion 
of patients diagnosed with cancer at 
an early stage (when it is still localised) 
across international jurisdictions suggest 
that investigating how cancer-associated 
symptoms are managed by primary 
care practitioners may be important in 
understanding and addressing international 
variation in cancer survival.1–8 Many 
countries have guidelines to advise primary 
care practitioners on the symptoms and 
signs of potential oncological significance 
that will require investigation or referral.9 
However, these guidelines lack a robust 
primary care evidence base10,11 and 
commentators caution that they are 
‘guidelines not tramlines’.12 
The five-day reduction in diagnostic delay 
observed in the UK since the introduction 
of the 2005 National Institute for Health 
and Care Excellence (NICE) guidelines for 
managing suspected cancer suggests that 
guidelines are important, but substantial 
variation persists in the median diagnostic 
interval between cancer types (26–
156 days).13 It is possible, therefore, that 
the presence of guidelines, the threshold 
risk for cancer at which the guideline 
recommends investigation or referral, and 
the adherence by clinicians to the guideline 
between countries, may contribute to the 
differences in cancer survival.13,14
The International Cancer Benchmarking 
Partnership (ICBP) seeks to understand 
how and why cancer survival varies 
between countries. Eleven jurisdictions in 
eight countries with universal access to 
health care via primary care practitioners 
participate: Australia (New South Wales 
and Victoria); Canada (British Columbia, 
Manitoba, and Ontario); Denmark; 
Norway; Sweden; and the UK (England, 
Northern Ireland, and Wales). Module 
three of the partnership (ICBP3) focuses 
on primary care and conducted a survey 
investigating systems and practice around 
the management of symptoms of cancer.15 
It included multistage vignettes involving 
patients presenting with symptoms 
suggestive of cancer. The full results are 
published elsewhere; a positive correlation 
was found in each jurisdiction between 
the primary care practitioner’s willingness 
to act definitively at an earlier stage of 
the scenarios and 1-year (and conditional 
5-year) survival rates.16
The researchers of this study wanted to 
explore international variations in cancer-
specific diagnostic guidance adherence by 
primary care practitioners. As such, the aim 
of this study was to: 
• delineate primary care practitioner 
cancer-specific diagnostic guidance in 
jurisdictions participating in the ICBP;
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Background
Variation in cancer survival persists between 
comparable nations and appears to be due, in 
part, to primary care practitioners (PCPs) having 
different thresholds for acting definitively in 
response to cancer-related symptoms. 
Aim
To explore whether cancer guidelines, and 
adherence to them, differ between jurisdictions 
and impacts on PCPs’ propensity to take definitive 
action on cancer-related symptoms. 
Design and setting
A secondary analysis of survey data from six 
countries (10 jurisdictions) participating in the 
International Cancer Benchmarking Partnership.
Method
PCPs’ responses to five clinical vignettes 
presenting symptoms and signs of lung (n = 2), 
colorectal (n = 2), and ovarian cancer (n = 1) 
were compared with investigation and referral 
recommendations in cancer guidelines.
Results
Nine jurisdictions had guidelines covering the 
two colorectal vignettes. For the lung vignettes, 
although eight jurisdictions had guidelines for 
the first, the second was covered by a Swedish 
guideline alone. Only the UK and Denmark had 
an ovarian cancer guideline. Survey responses 
of 2795 PCPs (crude response rate: 12%) were 
analysed. Guideline adherence ranged from 
20–82%. UK adherence was lower than other 
jurisdictions for the lung vignette covered by 
the guidance (47% versus 58%; P <0.01) but 
similar (45% versus 46%) or higher (67% versus 
38%; P <0.01) for the two colorectal vignettes. 
PCPs took definitive action least often when a 
guideline recommended a non-definitive action 
or made no recommendation. UK PCPs adhered 
to recommendations for definitive action less 
than their counterparts (P <0.01). There was 
no association between jurisdictional guideline 
adherence and 1-year survival.
Conclusion
Cancer guideline content is variable between 
similarly developed nations and poor guideline 
adherence does not explain differential 
survival. Guidelines that fail to cover high-risk 
presentations or that recommend non-definitive 
action may reduce definitive diagnostic action.
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• use the survey data to assess guideline 
adherence;
• specifically look at performance in the UK 
compared with other jurisdictions; and 
• assess whether adherence correlated 
with cancer survival.
METHOD
Data from British Columbia were excluded 
from this analysis as the ICBP3 survey 
in that locality was organised differently; 
as such, it was not possible to combine 
responses with other jurisdictions.
Survey
The survey was conducted between May 
2012 and July 2013. It contained five 
vignettes: 
• two for lung cancer;
• two for colorectal cancer; and 
• one for ovarian cancer.15 
Each vignette described a patient 
presenting to primary care and the 
sequential presentation of cancer-related 
symptoms in up to three stages. Primary 
care practitioners were asked to choose 
which action they would take at each stage. 
If they proposed definitive diagnostic action 
to confirm or rule out cancer at any stage, no 
further response was required. A definitive 
action was defined as any secondary care 
referral or a test undertaken in primary 
care with a high probability of diagnosing 
underlying cancer.15 Definitive tests were: 
• chest X-ray or computed tomography 
(CT) thorax for lung cancer;
• CT scan of abdomen or colonoscopy for 
colorectal cancer; and
• abdominal ultrasound, transvaginal 
ultrasound, or abdominal-pelvic CT scan 
for ovarian cancer. 
UK responders were asked additional 
questions about their use of, or attitudes 
towards, cancer guidelines.
Guideline identification 
Guidelines for the primary care investigation 
and referral of patients with suspected lung, 
colorectal, and ovarian cancer in use at the 
time of the survey were identified (details 
available from the authors on request). 
The recommended actions corresponding 
to each stage of the vignettes were 
extracted by the lead author and verified 
by two others. Any disagreements were 
resolved by discussion. The same NICE 
guidance (CG27) was used in all included 
UK jurisdictions.
Calculating adherence. The actions 
recommended by the jurisdictional 
guideline were compared with the action 
proposed by the survey responders. If more 
than one action was recommended by the 
guidance (for example, colonoscopy or 
referral) choice of either by the primary care 
practitioner was classified as adherence. If 
the guideline was ambiguous about timing, 
a ‘persistent symptom’ was interpreted as 
meaning one that was present for >3 weeks 
and ‘recent onset’ was defined as being 
within 6 months. In the context of the second 
lung cancer vignette, an upper respiratory 
tract infection was accepted as a potential 
explanation for the presence of cough. 
The number of primary care practitioners 
who chose to take a definitive action was 
assessed, irrespective of whether this 
action was recommended by the guideline. 
Adherence was only measured for stage 
one of each vignette (details available from 
the authors on request) as definitive action 
ended the vignette for that responder; 
consequently there was a significant 
attrition in the number of responders after 
stage one.15 
Analysis. To identify factors that may 
contribute to the relatively low survival 
rates observed in the UK, pooled estimates 
for adherence and definitive action were 
compared for UK jurisdictions and their 
non-UK counterparts. The estimate for 
each jurisdiction was weighted by the 
inverse of the variance to allow for variation 
in sample sizes. Statistical significance was 
assessed using the Z-test. 
The association between 1-year survival 
for each of the vignettes with applicable 
guidelines was investigated using 
scatterplots; simple linear regression and 
the R  2 statistic were used to explore the 
strength of association. Routinely collected 
How this fits in
Primary care cancer guidelines exist 
internationally to prompt the investigation 
and referral of patients who are 
symptomatic, but guideline content 
is variable. Primary care practitioner 
adherence to current guidelines does 
not explain differences in cancer survival, 
but guidelines that fail to cover high-risk 
presentations or recommend non-definitive 
action may, by contributing to a lack of 
definitive diagnostic action, be causing false 
reassurance and diagnostic delay.
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jurisdictional survival data for 2007 were 
used for the analyses.1 Multivariate analysis 
was not feasible as these are population-
level data and a limited number of data 
points were available. 
An a priori sensitivity analysis was 
performed; Denmark was excluded as its 
health system had undergone significant 
redevelopment since the publication of the 
2007 survival estimates.17 All analyses were 
conducted in Microsoft Excel (2010) and 
Stata (version 12).
The UK survey responders’ additional 
responses regarding guideline adherence 
were analysed descriptively. 
RESULTS
In total, 2795 primary care practitioners 
from the 10 jurisdictions (six countries) 
included in this analysis completed the 
survey (crude response rate, 12%).16
Lung cancer
Eight of the 10 jurisdictions had a lung cancer 
guideline: seven gave recommendations 
applicable to the first vignette but only one, 
from Sweden, covered the second. Most 
guidelines defined 3 weeks as the interval 
after which action was recommended for 
an unexplained cough, although the Danish 
guideline quoted 4 weeks and the Swedish 
guideline recommended a ‘low threshold’ 
for action.
For vignette 1, primary care practitioner 
guideline adherence ranged from 42% to 
83%, with lower adherence in UK (England, 
Northern Ireland, and Wales) compared 
with non-UK jurisdictions (47% versus 
58%, P <0.01). Estimates of adherence are 
similar to estimates of definitive action: in 
all cases a chest X-ray was recommended 
(a definitive action) and this is what primary 
care practitioners almost invariably 
proposed. 
Although the risk of lung cancer was four 
times higher in the second vignette (with 
a positive predictive value of 3.6% versus 
0.9%) the lack of applicable guidelines may 
have contributed to the much lower rate of 
proposed definitive action (Table 1). 
Colorectal cancer 
Nine jurisdictions had guidelines covering 
the two colorectal cancer vignettes but they 
recommended different actions (Table 2). 
Three guidelines covering five jurisdictions 
advised a full blood count as the first step 
in both vignettes, while the remaining 
guidelines recommended colonoscopy 
or specialist referral. Two guidelines 
recommending a full blood count (Ontario 
and the UK) also include formal diagnostic 
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algorithms based on specified time intervals 
and symptom trajectories. In contrast, the 
guidelines from countries recommending 
immediate definitive action (Australia and 
Sweden) were more narrative, describing 
symptoms and indications for investigation 
but encouraging primary care practitioners 
to make their own clinical assessment of 
cancer risk. 
Primary care practitioner adherence to 
colorectal cancer guidelines varied from 
20% to 74% across jurisdictions: it was 
higher when ordering a full blood count (38–
74%) than when arranging a colonoscopy 
or referral (20–39%). Adherence was no 
different between the UK and non-UK 
jurisdictions for vignette 3 (45% versus 46%, 
P = 0.73), but was higher for vignette 4 (67% 
versus 38%, P <0.01). In accordance with 
the guidelines, definitive diagnostic action 
was taken substantially less frequently by 
UK than non-UK primary care practitioners 
in response to both vignettes (8% versus 
34% for vignette 3, P <0.01; 16% versus 27% 
for vignette 4, P <0.01).
Ovarian cancer
The UK and Denmark (four jurisdictions) 
were the only ones that had guidelines 
for a diagnosis of ovarian cancer. No 
recommendations relevant to the vignette 
scenario were included, so guideline 
adherence cannot explain the differential 
survival for ovarian cancer. However, as 
with lung and colorectal cancer, there was 
a substantial difference between UK and 
non-UK primary care practitioners in the 
propensity to take definitive diagnostic 
action (38% versus 61%, P <0.01) (Table 3).
Scatterplots and sensitivity analysis
Scatterplots showed no association 
between guideline adherence and 
jurisdictional 1-year survival (R  2 = <0.01 
to 0.26; details available from the authors 
on request). Excluding Denmark from our 
analyses (to reduce the influence of health 
system redevelopment) made no clinically 
important or statistically significant 
difference to either the pooled results 
shown in Tables 1–3, or to the reported lack 
of association between guideline adherence 
and 1-year survival.
Adherence to UK guidelines
One-quarter of the 639 UK primary care 
practitioners surveyed (28%, n = 180) 
reported referring to cancer guidelines 
‘usually’ or ‘always’, whereas 8% (n = 51) 
said they rarely or never acted outside 
of them. Half thought the removal of 
guidelines would result in no change in 
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referrals (51%, n = 325). Nine out of 10 
UK primary care practitioners stated they 
would ignore the guidance if they thought 
a patient had cancer but their symptom 
profile did not fit the urgent referral criteria 
(Figure 1); 20% (n = 128) of these said they 
would ‘record the patient’s history and 
symptoms in a way that allows them to fit 
the guidelines for urgent referral’. 
DISCUSSION
Summary
Guidelines were available in most ICBP 
jurisdictions for the primary care 
assessment of lung and colorectal 
cancer symptoms. Advice applicable to 
the lung cancer vignettes was identical 
where defined, but for colorectal cancer 
the recommended actions varied. Only 
Denmark and the UK jurisdictions had 
guidelines for ovarian cancer. Guideline 
adherence ranged from 20% to 82% across 
vignettes. 
The findings presented here demonstrate 
that there are several differences between 
jurisdictions: 
• some do not have guidelines for every 
clinical scenario covered by this study; 
• the threshold for definitive action varies; 
and 
• a significant anomaly exists in the lung 
cancer guidelines — investigation was 
recommended at a low positive predictive 
value (PPV) in one vignette but not in 
another with a higher PPV.
UK adherence was significantly lower 
than non-UK jurisdictions when a definitive 
action was recommended, and significantly 
higher (or equivocal) for a non-definitive 
recommendation. Differences in the 
emphasis placed on how strictly clinicians 
are expected to follow guidelines may 
explain the variation in adherence: the UK’s 
NICE guidance sets out clear symptoms on 
which to base specific actions on, and the 
Canadian guidelines are more algorithm- 
based. The Swedish and Norwegian 
guidelines are less directive than the UK 
and Canadian guidelines, leaving more to 
clinical judgement. Differences in approach 
partly represent how well equipped a 
healthcare system is to carry out definitive 
tests, with pathways written with these 
constraints in mind.18
One in five UK primary care practitioners 
admitted to reporting a symptom profile 
that fit the referral criteria if they were 
concerned about the possibility of cancer 
regardless of the presenting symptom 
profile. This perhaps reflects primary care 
practitioners’ recognition of the limitations 
of uniform disease-specific referral 
guidance and a willingness to bend the 
rules.19 It does not indicate whether UK 
primary care practitioners are bending the 
rules for the ‘right’ patients or whether this 
is also the case in other jurisdictions. 
Non-UK primary care practitioners 
were more likely to act definitively outside 
of guidelines than UK primary care 
practitioners: Sweden has some of the 
highest 1-year survival rates, perhaps 
explained by its relatively high rate of 
definitive action despite one of the lowest 
guideline adherence rates. Conversely, 
England had the highest rates of adherence, 
a low rate of definitive action, and low 
survival rates. 
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Figure 1. UK primary care practitioners’ response to the question ‘What would you do if you suspect cancer and 
yet the patient does not reflect guideline referral criteria?’
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Despite these observations, the findings 
demonstrated no relationship between 
guideline adherence and cancer survival. 
This is unsurprising as the effect of 
guidelines on survival is multifaceted, 
determined by the threshold for referral or 
investigation, adherence, and the actions 
taken by primary care practitioners for cases 
that fall outside the guidelines. Variables 
additional to the primary care interval that 
were not taken into account in this analysis 
also influence survival outcomes; these 
include the patient and system intervals, 
patient factors such as comorbidity, and 
treatment received.3,7,8
Strengths and limitations 
To the authors’ knowledge, this is the first 
study to compare the clinical decisions 
of primary care practitioners in relation 
to primary care cancer guidelines and 
1-year survival. Data from a recent, large 
validated international survey of primary 
care practitioners developed by primary 
care cancer experts were used.15 The main 
limitations of this analysis are: 
• sampling methods between jurisdictions 
were variable;16 
• the response rate was low, ranging from 
5.5% (England) to 45.6% (Manitoba);16 
• responders were not totally representative 
of the primary care practitioners in all 
jurisdictions;16 
• there is a risk that the UK researchers 
involved in this analysis have incorrectly 
interpreted each jurisdiction’s guidelines; 
• primary care practitioners were not 
required to access guidelines when 
completing the survey, although this 
could closely resemble clinical practice 
as one-quarter of UK GPs said they 
‘usually’ referred to guidelines.
Comparison with existing literature
Guideline adherence was lower for the UK 
primary care practitioners in the current 
study compared with the 18 775 urgent 
referrals audited across 516 Scottish GP 
practices, for which adherence ranged 
from 75–94% depending on cancer type.20 
However, the Scottish analysis only included 
referred cases and so adherence to non-
definitive and definitive actions other than 
referral were not included.20 
The findings presented here support 
the ICBP316 by suggesting that cancer 
guidelines may have a modifying effect on 
primary care practitioner desire to refer 
or undertake a definitive investigation. 
Adherence to guidance that will not confirm 
a suspected diagnosis (for example, full 
blood count) may inhibit definitive action 
(for example, colonoscopy), and false 
reassurance may be given, preventing 
definitive action when a guideline does not 
cover the clinical scenario in question. 
This survey supports the findings of 
Cook and colleagues, who interviewed 39 
primary care staff in six practices; their 
results suggested uniform guidelines fail to 
wholly resolve risk management in primary 
care. GPs ‘fudge’, ‘embellish’, or ‘bend the 
rules’ to ensure assessment of patients 
for whom they have concerns but who 
did not meet the rigid referral criteria.21 
The findings presented here also suggest 
some primary care practitioners share 
the view of patients, who would prefer to 
be investigated for suspected cancer at a 
much lower risk threshold than is currently 
used,22 a preference taken into account in 
the 2015 NICE guidelines update.18
Implications for research and practice
The evidence base underpinning primary 
care guidelines should be reviewed to 
prioritise research in primary care cancer 
diagnosis and to determine whether a 
standardised clinical guideline should be 
developed for all jurisdictions, with explicit 
thresholds for referral or investigation. 
Interpreting the guidelines to assess 
primary care practitioner adherence also 
emphasised the potential difficulty in 
interpreting three commonly used, if not 
precisely defined, terms: 
• ‘persistent’ symptoms;
• ‘unexplained’ symptoms; and 
• ‘recent onset’. 
Primary care practitioner guidelines for 
cancer work-up should take care to use 
language that does not restrict action in 
cases where risk factors exist or patients 
have symptoms that are less well defined. 
Research into efficient pathways for 
definitive investigation of those patients 
who do not meet current referral criteria 
but who primary care practitioners perceive 
might have cancer appears particularly 
important.23 Further work should investigate 
whether strict adherence to available 
guidance reduces the primary care interval 
when compared with clinical judgement 
alone, and which strategies could be 
implemented to overcome the mechanisms 
leading to missed opportunities for earlier 
cancer diagnosis, for example, by drawing 
on expertise in human factors science and 
informatics.24,25 
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In the UK, primary care practitioner 
guideline uptake should be studied during 
the rollout of the 2015 NICE guideline18 to 
identify which factors determine adherence 
and non-adherence, and which techniques 
are used to ‘safety net’ when guideline 
criteria are not satisfied.
Considerable variation exists in primary 
care cancer guideline content, and 
adherence to current guidelines is not, at 
present, a major factor in the difference in 
cancer survival rates between countries. 
The effect of referral guidelines for 
suspected cancer on survival is determined 
by the recommended threshold for 
referral or investigation, the primary care 
practitioner’s adherence to guidelines, 
and the actions taken by primary care 
practitioners for cases that fall outside of 
the guidelines. However, guidelines that fail 
to cover high-risk presentations or those 
that recommend non-definitive action 
may be causing false reassurance and 
diagnostic delay, contributing to a lack of 
definitive diagnostic action by primary care 
practitioners.
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